What is it about?
In patients with more than two sites of metastatic disease, the progression free survival was almost the same compared with the pivotal trial.
Featured Image
Why is it important?
It is a good alternative and tolerate in first line treatment of RCC
Perspectives
Read the Original
This page is a summary of: Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma, OncoTargets and Therapy, September 2016, Dove Medical Press,
DOI: 10.2147/ott.s109445.
You can read the full text:
Contributors
The following have contributed to this page